Product Overview

Siphene M 25 mg is a prescription medication specifically indicated for the treatment of female infertility caused by ovulatory dysfunction. Produced by the Serum Institute of India, each strip contains 30 tablets of clomiphene citrate, a well‑characterized selective estrogen receptor modulator (SERM). The drug is supplied in an oral tablet form and is intended for short‑term use under medical supervision. This overview presents the commercial and clinical perspective for patients and healthcare providers seeking a reliable fertility aid.

What is Siphene M 25 mg?

Siphene M denotes the brand name of clomiphene citrate USP 25 mg tablets. Clomiphene citrate is a non‑steroidal compound that functions as a partial agonist/antagonist at estrogen receptors in the hypothalamus and pituitary gland. By blocking the negative feedback of estrogen, it stimulates the hypothalamic release of gonadotropin‑releasing hormone (GnRH), which subsequently increases luteinizing hormone (LH) and follicle‑stimulating hormone (FSH) secretion from the anterior pituitary. The resulting hormonal environment promotes the development of multiple ovarian follicles and facilitates ovulation in women who otherwise would not release an egg.

Uses and Benefits

The primary clinical application of Siphene M 25 mg is the management of oligomenorrhea and anovulation associated with polycystic ovary syndrome (PCOS), idiopathic infertility, or other endocrine disturbances. According to data reviewed by the National Institutes of Health, clomiphene citrate successfully induces ovulation in roughly 40‑45 % of treatment cycles, and pregnancy rates of 10‑15 % per cycle have been documented when the medication is used according to established protocols. Benefits include an oral dosing route, low acquisition cost, and a long history of safety when monitored by a qualified clinician. In many fertility programs, Siphene M is considered a first‑line agent before more invasive interventions such as gonadotropin therapy or assisted reproductive technology. Clinical studies have demonstrated that when combined with lifestyle modifications such as weight management and exercise, ovulation rates can improve further, especially in overweight patients with PCOS. Additionally, the medication has been shown to improve endometrial receptivity when used in conjunction with timely intercourse or intrauterine insemination, thereby enhancing overall pregnancy outcomes.

How It Works

Clomiphene citrate exerts its pharmacodynamic effect by selectively modulating estrogen receptors in the central nervous system. In low‑estrogen environments, the drug acts as an agonist, prompting the hypothalamus to increase GnRH pulsatility. This cascade leads to heightened LH and FSH output, which stimulate the growth of ovarian follicles. The medication does not directly act on ovarian tissue; rather, it creates a favorable endocrine milieu that enables natural ovulation. The mechanism of action is well documented in peer‑reviewed literature, including systematic reviews indexed on PubMed and summarized in the NIH’s clinical guidelines for infertility management.

Dosage Guidelines

Standard therapeutic regimens commence with a single 25 mg tablet taken daily for five consecutive days, typically initiated on day 3 to day 5 of the menstrual cycle. The dosage may be repeated in subsequent cycles, with adjustments made based on ovarian response documented by transvaginal ultrasound or serum estradiol measurements. The maximum recommended daily dose is 100 mg, but most clinicians limit treatment to 25 mg to reduce the risk of multiple gestations and ovarian hyperstimulation. Patients should be monitored for follicular development, and therapy is usually discontinued after three to six ovulatory cycles if pregnancy has not been achieved, per the recommendations of the U.S. FDA and professional societies. Follicular monitoring is recommended starting on day 6 or 7 of the cycle to assess follicular growth; when a leading follicle reaches 18‑20 mm in diameter, timed intercourse or controlled ovarian insemination can be scheduled. If no response is observed after three cycles, a dose escalation to 50 mg daily may be considered under medical supervision, but clinicians are advised to limit escalation to minimize the risk of ovarian hyperstimulation.

Side Effects

Adverse reactions to clomiphene citrate are generally mild and transient. The most frequently reported side effects include hot flashes, abdominal bloating, breast tenderness, and brief visual disturbances such as blurred vision. Less common but clinically significant events comprise ovarian hyperstimulation syndrome (OHSS), the formation of functional ovarian cysts, and an increased propensity for thromboembolic phenomena. The FDA advises immediate discontinuation of the medication if patients experience severe pelvic pain, shortness of breath, visual changes, or signs of blood clotting. Most side effects resolve after the drug is cleared from the system.

Warnings and Precautions

Siphene M is contraindicated in individuals with a known hypersensitivity to clomiphene citrate or any excipients in the formulation. It should not be used in patients with active liver disease, ovarian cysts unrelated to PCOS, or abnormal uterine bleeding of undetermined origin. The medication is also contraindicated during pregnancy, as fetal exposure may lead to adverse developmental outcomes. Prior to initiation, a comprehensive medical assessment—including baseline pelvic ultrasound, hormonal profiling, and a review of medical history—is essential. Concomitant use with other ovulation‑inducing agents is discouraged without specialist oversight, and patients should be counselled about the increased risk of multiple pregnancies associated with higher doses. Patients should be advised to avoid concomitant use of estrogens, progestins, or other hormonal therapies unless explicitly prescribed, as these may alter the expected pharmacodynamic response. Additionally, individuals with a history of thromboembolic disease should undergo a thorough risk‑benefit assessment before initiating treatment, given the potential for increased clotting factors.

Frequently Asked Questions

1. How long does it take to see ovulation after starting Siphene M? Ovulation typically occurs 6‑12 days after the final dose, but individual response varies; ultrasound monitoring provides the most reliable confirmation of ovulatory timing.
2. Can Siphene M be used for male infertility? No, this formulation is specifically indicated for female ovulatory disorders; separate clomiphene products are formulated for male hypogonadism and are not interchangeable.
3. Is a prescription required to purchase Siphene M 25 mg? Yes, a licensed healthcare provider must evaluate eligibility and issue a prescription before the medication can be dispensed.
4. What storage conditions are recommended for the tablets? Store the tablets at room temperature, away from moisture and direct sunlight, and keep the strip sealed until ready for use.
5. Are there any dietary restrictions while taking Siphene M? No specific dietary modifications are required; however, maintaining adequate hydration and a balanced nutrition plan supports overall reproductive health.

For authoritative clinical guidance, refer to the U.S. Food and Drug Administration, the MedlinePlus database, and the National Institutes of Health publications on infertility treatment. Consultation with a reproductive endocrinologist is recommended for complex cases or when assisted reproductive technologies are being considered.

Related Products

• CB-Lin (Cabergoline)
• Meprate 10 mg (Medroxyprogesterone)
• Sicriptin 2.5 mg Tablets (Bromocriptine)
• Sicriptin 1.25 mg Tablets (Bromocriptine)
• Sicriptin (Bromocriptine)
• Bromocriptine 1.25 mg (Generic)
• Bromocriptine 2.5 mg (Generic)
• ZyhCG 10000 (HCG 10000iu)
• ZyhCG 5000 (HCG 5000iu)
• ZyhCG 2000 (HCG 2000iu)
• Sifasi Aqua 5000 (HCG (Human Chorionic Gonadotropin))
• Clomiphene 50 mg (Generic)